INTRODUCTION: To evaluate the safety and efficacy of Thulium VapoEnucleation of the prostate (ThuVEP) for patients on oral anticoagulants (OA) with symptomatic benign prostatic obstruction (BPO). METHODS: Fifty-six patients, undergoing ThuVEP at two institutions, were evaluated from May 2009 until June 2011. All patients were at high cardiopulmonary risk and presented with a median American Society of Anesthesiology score of 3 [interquartile range (IQR) 2-3]. Thirty-two patients were on aspirin, 8 were on clopidogrel or clopidogrel and aspirin, and 16 on phenprocoumon at the time of surgery. Patient demographic, perioperative, and follow-up data were analyzed. RESULTS: Median prostate volume was 50 (IQR 34-76) cc, and resected tissue weight was 32 (IQR 20-50) g. The median operative time was 61.5 (IQR 40-100.75) min, and the catheter time 2 (IQR 2-3) days. There were no perioperative thromboembolic events. Five patients (8.9%) required a second-look operation in the immediate postoperative course (hemorrhage n = 4, residual adenoma n = 1) and four (7.1%) blood transfusions. Complications within the first 30 days included urinary tract infections (1.7%), urinary retention (3.6%), and delayed bleeding (7.1%). These complications were managed conservatively. At 12-month follow-up, median QoL [5 (IQR 3.75-5) vs. 1 (IQR 1-2)], IPSS [21.5 (IQR 15.5-23.75) vs. 5 (IQR 3-8)], Qmax [7.7 (IQR 6.3-10) vs. 28.3 (IQR 21.25-39.2) ml/s], and postvoiding residual urine [100 (IQR 46-200) vs. 17.5 (IQR 0-36) ml] improved significantly (p < 0.002). CONCLUSIONS: Thulium VapoEnucleation of the prostate seems to be a safe and efficacious procedure for the treatment of symptomatic BPO in patients at high cardiopulmonary risk on OA.
INTRODUCTION: To evaluate the safety and efficacy of Thulium VapoEnucleation of the prostate (ThuVEP) for patients on oral anticoagulants (OA) with symptomatic benign prostatic obstruction (BPO). METHODS: Fifty-six patients, undergoing ThuVEP at two institutions, were evaluated from May 2009 until June 2011. All patients were at high cardiopulmonary risk and presented with a median American Society of Anesthesiology score of 3 [interquartile range (IQR) 2-3]. Thirty-two patients were on aspirin, 8 were on clopidogrel or clopidogrel and aspirin, and 16 on phenprocoumon at the time of surgery. Patient demographic, perioperative, and follow-up data were analyzed. RESULTS: Median prostate volume was 50 (IQR 34-76) cc, and resected tissue weight was 32 (IQR 20-50) g. The median operative time was 61.5 (IQR 40-100.75) min, and the catheter time 2 (IQR 2-3) days. There were no perioperative thromboembolic events. Five patients (8.9%) required a second-look operation in the immediate postoperative course (hemorrhage n = 4, residual adenoma n = 1) and four (7.1%) blood transfusions. Complications within the first 30 days included urinary tract infections (1.7%), urinary retention (3.6%), and delayed bleeding (7.1%). These complications were managed conservatively. At 12-month follow-up, median QoL [5 (IQR 3.75-5) vs. 1 (IQR 1-2)], IPSS [21.5 (IQR 15.5-23.75) vs. 5 (IQR 3-8)], Qmax [7.7 (IQR 6.3-10) vs. 28.3 (IQR 21.25-39.2) ml/s], and postvoiding residual urine [100 (IQR 46-200) vs. 17.5 (IQR 0-36) ml] improved significantly (p < 0.002). CONCLUSIONS:Thulium VapoEnucleation of the prostate seems to be a safe and efficacious procedure for the treatment of symptomatic BPO in patients at high cardiopulmonary risk on OA.
Authors: Thorsten Bach; Rolf Muschter; Roland Sroka; Stavros Gravas; Andreas Skolarikos; Thomas R W Herrmann; Thomas Bayer; Thomas Knoll; Claude-Clément Abbou; Guenter Janetschek; Alexander Bachmann; Jens J Rassweiler Journal: Eur Urol Date: 2011-10-21 Impact factor: 20.096
Authors: Aurélien Descazeaud; Gregoire Robert; Abdel Rahmene Azzousi; Charles Ballereau; Bertrand Lukacs; Olivier Haillot; Olivier Dumonceau; Marian Devonec; Marc Fourmarier; Christian Saussine; Alexandre de la Taille Journal: BJU Int Date: 2009-12-22 Impact factor: 5.588
Authors: Mariolyn D Raj; Colleen McDonald; Andrew J Brooks; Malcolm Drummond; Howard M Lau; Manish I Patel; Simon V Bariol; Audrey C Wang; Henry H Woo Journal: Urology Date: 2011-09-08 Impact factor: 2.649
Authors: Sascha A Ahyai; Peter Gilling; Steven A Kaplan; Rainer M Kuntz; Stephan Madersbacher; Francesco Montorsi; Mark J Speakman; Christian G Stief Journal: Eur Urol Date: 2010-06-11 Impact factor: 20.096
Authors: William W Tinmouth; Enmar Habib; Samuel C Kim; Ramsay L Kuo; Ryan F Paterson; Colin L Terry; Mostafa Elhilali; James E Lingeman Journal: J Endourol Date: 2005-06 Impact factor: 2.942
Authors: Zohar A Dotan; Yoram Mor; Ilan Leibovitch; David Varon; Jacob Golomb; Mordechai Duvdevani; Jacob Ramon Journal: J Urol Date: 2002-08 Impact factor: 7.450
Authors: Jesco Pfitzenmaier; Christian Gilfrich; Maria Pritsch; Daniela Herrmann; Stephan Buse; Axel Haferkamp; Nenad Djakovic; Sascha Pahernik; Markus Hohenfellner Journal: BJU Int Date: 2008-04-16 Impact factor: 5.588
Authors: Luciano Macchione; Giuseppe Mucciardi; Alessandro Gali'; Antonina Di Benedetto; Salvatore Butticè; Carlo Magno Journal: Int Urol Nephrol Date: 2013-07-27 Impact factor: 2.370
Authors: Christopher Netsch; B Becker; C Tiburtius; C Moritz; A Venneri Becci; T R W Herrmann; A J Gross Journal: World J Urol Date: 2017-07-11 Impact factor: 4.226